Published in J Cell Physiol on February 01, 2013
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol (2013) 1.23
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol (2013) 1.04
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer (2014) 0.94
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med (2015) 0.86
Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer (2014) 0.83
Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. J Exp Clin Cancer Res (2015) 0.81
Fluorinated N,N'-diarylureas as AMPK activators. Bioorg Med Chem Lett (2013) 0.78
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol (2015) 0.77
Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol (2016) 0.77
Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther (2015) 0.76
Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases. Mol Clin Oncol (2016) 0.75
Targeting gastrointestinal stromal tumors: the role of regorafenib. Onco Targets Ther (2016) 0.75
Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via NF-κB inactivation in SK-Hep1 cells. Oncol Lett (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell (2005) 21.01
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer (2011) 3.88
The dynamic nature of autophagy in cancer. Genes Dev (2011) 3.57
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73
Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol (2011) 2.52
Does tumour dormancy offer a therapeutic target? Nat Rev Cancer (2010) 2.19
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer (2010) 2.13
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol (2006) 1.95
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol (2007) 1.63
ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res (2011) 1.44
Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol (2010) 1.42
Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos (2010) 1.27
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer (2010) 1.10
Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol (2002) 0.99
RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology (2011) 0.97
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97
Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs (2010) 0.86
Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett (2000) 0.83
Hsp90 prevents phenotypic variation by suppressing the mutagenic activity of transposons. Nature (2010) 2.44
A comparative study between conventional and laparoscopic cholecystectomy: evaluation of phagocytic and T-cell-mediated antibacterial activities. J Clin Gastroenterol (2002) 1.38
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol (2003) 1.34
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol (2013) 1.04
REST: an oncogene or a tumor suppressor? Trends Cell Biol (2013) 0.98
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res (2005) 0.98
Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol (2006) 0.97
Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res (2005) 0.97
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer (2014) 0.94
Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacol Immunotoxicol (2009) 0.94
Investigations on cellular proliferation induced by zearalenone and its derivatives in relation to the estrogenic parameters. Toxicol Lett (2005) 0.94
Rapid neurite outgrowth in neurosecretory cells and neurons is sustained by the exocytosis of a cytoplasmic organelle, the enlargeosome. J Cell Sci (2009) 0.92
A signaling loop of REST, TSC2 and β-catenin governs proliferation and function of PC12 neural cells. J Cell Sci (2011) 0.90
Astrocyte stellation, a process dependent on Rac1 is sustained by the regulated exocytosis of enlargeosomes. Glia (2011) 0.89
Structure, regulation and evolution of the crystal-Stellate system of Drosophila. Genetica (2003) 0.89
Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line. Lipids Health Dis (2011) 0.89
REST/NRSF-mediated intrinsic homeostasis protects neuronal networks from hyperexcitability. EMBO J (2013) 0.88
Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol (2008) 0.88
REST/NRSF governs the expression of dense-core vesicle gliosecretion in astrocytes. J Cell Biol (2011) 0.88
Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell line. Genes Nutr (2008) 0.87
Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology (2004) 0.87
Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. Anticancer Res (2010) 0.87
Effects of genistein on the polyamine metabolism and cell growth in DLD-1 human colon cancer cells. Nutr Cancer (2005) 0.87
Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Lipids Health Dis (2010) 0.86
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. J Gastroenterol (2002) 0.86
Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
Effects of Lactobacillus rhamnosus GG on the cell growth and polyamine metabolism in HGC-27 human gastric cancer cells. Nutr Cancer (2007) 0.86
Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer. BMC Cancer (2006) 0.84
DmMyD88 controls dorsoventral patterning of the Drosophila embryo. EMBO Rep (2003) 0.84
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer (2014) 0.83
The rest repression of the neurosecretory phenotype is negatively modulated by BHC80, a protein of the BRAF/HDAC complex. J Neurosci (2009) 0.83
Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. Dig Dis Sci (2002) 0.83
KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. Anticancer Res (2010) 0.83
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther (2011) 0.82
Quercetin inhibits human DLD-1 colon cancer cell growth and polyamine biosynthesis. Anticancer Res (2010) 0.82
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells. Scand J Gastroenterol (2005) 0.82
A new form of neurite outgrowth sustained by the exocytosis of enlargeosomes expressed under the control of REST. Traffic (2010) 0.81
Involvement of estrogen receptor-related receptors in human ovarian endometriosis. Fertil Steril (2011) 0.81
Assessment of estrogen receptors and apoptotic factors in cryopreserved human ovarian cortex. Syst Biol Reprod Med (2009) 0.81
Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line. Fitoterapia (2008) 0.80
Dual REST-dependence of L1CAM: from gene expression to alternative splicing governed by Nova2 in neural cells. J Neurochem (2012) 0.79
N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB J (2006) 0.79
Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Des (2003) 0.79
Potential role of the steroid receptor pattern in the response of inoperable intra-abdominal desmoid to toremifene after failure of tamoxifen therapy. Int J Colorectal Dis (2009) 0.79
Parathyroid hormone determination in ultrasound-guided fine needle aspirates allows the differentiation between thyroid and parathyroid lesions: our experience and review of the literature. Endocr Metab Immune Disord Drug Targets (2013) 0.78
NGF signaling in PC12 cells: the cooperation of p75(NTR) with TrkA is needed for the activation of both mTORC2 and the PI3K signalling cascade. Biol Open (2013) 0.78
Antiproliferative, antioxidant and anti-inflammatory effects of hydroxytyrosol on human hepatoma HepG2 and Hep3B cell lines. Anticancer Res (2012) 0.78
A significant role of lipogenic enzymes in colorectal cancer. Anticancer Res (2012) 0.78
N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1. Int J Cancer (2009) 0.77
Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. Anticancer Agents Med Chem (2014) 0.77
Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol Rep (2010) 0.77
Apoptosis in normal ovaries of women with and without endometriosis. Reprod Biomed Online (2009) 0.76
Differentiated thyroid carcinoma and intestinal polyposis syndromes. Endocr Metab Immune Disord Drug Targets (2012) 0.75
Antitumorigenic effect of dietary natural compounds via lipid metabolism modulation in Apc(Min/+) mice. Anticancer Res (2013) 0.75
Post-mortem Peyer's patches: their potential application in forensic medicine. Immunopharmacol Immunotoxicol (2009) 0.75
Postmortem morphology and viability of human Peyer's patches in distal ileum: a technical note. Immunopharmacol Immunotoxicol (2009) 0.75